Related Experiment Video
Updated: Sep 12, 2025
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
23.3K
Two Botulinum Toxin A Injections in Patients With Chronic Orofacial Myalgia: A Randomised, Double-Blind, Controlled
Christine Lennartsson1,2, Ellie Saghafi3,4, Behnosh Öhrnell Malekzadeh4,5
1Clinic of Orofacial Pain, Mölndal, Public Dental Service, Region Västra Götaland, Sweden.
Journal of Oral Rehabilitation
|August 6, 2025
Summary
Botulinum toxin A injections did not provide additional pain relief for chronic orofacial myalgia compared to saline. This study found no significant difference in pain reduction between the two treatments.
Area of Science:
- Neurology
- Pain Management
- Pharmacology
Background:
- Chronic orofacial myalgia presents a treatment challenge, as conventional methods are not always effective.
- Identifying novel therapeutic strategies is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the pain-reducing efficacy of two botulinum toxin A injections.
- To assess the effectiveness in patients with chronic orofacial myalgia refractory to conservative treatment.
Main Methods:
- A randomized, double-blind, placebo-controlled, multicenter study.
- 18+ year olds with chronic orofacial myalgia received two injections of botulinum toxin A or saline.
- Follow-up assessments occurred at multiple intervals up to nine months post-injection.
Main Results:
- A significant decrease in visual analog scale (VAS) pain intensity was observed in both groups from baseline.
- No statistically significant difference in pain reduction was found between the botulinum toxin A and saline groups.
Conclusions:
- Botulinum toxin A did not demonstrate superior pain relief compared to saline for chronic orofacial myalgia.
- Further research may be needed to explore alternative or adjunctive treatments.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
1.9K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.9K
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
761
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
761
01:31Skeletal Muscle Relaxants: Therapeutic Uses
617
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
617
01:15Myasthenia Gravis: Diagnostic Tests
1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K
01:21Skeletal Muscle Relaxants: Adverse Effects
471
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
471